Patrick Travis, MD
Hematology & Oncology · Fayetteville, ARNPI 1104897099
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 38.3% of the total. Reporting peaked in 2019 at $15,330 and has fallen 94.7% since, to $812 in 2025. Among hematology & oncology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $82.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Karyopharm Therapeutics Inc.$5K
- Rigel Pharmaceuticals, Inc.$4K
- Sanofi$4K
- Bristol Myers Squibb$2K
- GSK$2K
- plus $7K from 54 others
Across 134 payments — averaging $5311.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$321K
- TG Therapeutics, Inc.$177K
- AbbVie$116K
- Genentech, Inc.$70K
- Novartis$20K
- Bayer$5K
- plus $4K from 1 others
What the payments were for
- Consulting fees$6,78018%
- Speaking & faculty fees$21,35058%
- Travel & lodging$1,9845%
- Food & beverage$6,64118%
- Education$2591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,013 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 88 | $1,972,606 |
| RevlimidLenalidomide | 90 | $1,458,885 |
| CalquenceAcalabrutinib Maleate | 72 | $1,087,566 |
| JakafiRuxolitinib Phosphate | 50 | $818,637 |
| CabometyxCabozantinib S-Malate | 18 | $443,691 |
| NinlaroIxazomib Citrate | 34 | $433,370 |
| BrukinsaZanubrutinib | 27 | $363,870 |
| TasignaNilotinib Hcl | 15 | $299,984 |
| XtandiEnzalutamide | 14 | $194,124 |
| VerzenioAbemaciclib | 12 | $174,602 |
| PromactaEltrombopag Olamine | 13 | $170,484 |
| VenclextaVenetoclax | 15 | $149,198 |
| Lenalidomide | 14 | $148,301 |
| XareltoRivaroxaban | 89 | $66,205 |
| ThalomidThalidomide | 11 | $49,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $75 | $1,972,60688 claims |
| Bristol Myers SquibbRevlimid, Thalomid | $2,155 | $1,508,364101 claims |
| AstraZenecaCalquence | $268 | $1,087,56672 claims |
| Incyte CorporationJakafi | $50 | $818,63750 claims |
| NovartisTasigna, Promacta | $244 | $470,46728 claims |
| Exelixis Inc.Cabometyx | $88 | $443,69118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Vyvanse | $14,177 | $438,17647 claims |
| Astellas Pharma US IncXtandi | $198 | $194,12414 claims |
| Lilly USA, LLCVerzenio | $70 | $174,60212 claims |
| AbbVieVenclexta, Synthroid | $83 | $150,50336 claims |
| Johnson & JohnsonXarelto | $1,260 | $66,20589 claims |
| PfizerEliquis, Abrysvo | $28 | $50,49375 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fayetteville
- Eric SchaeferFayetteville$466K
- Stephan RosenfeldFayetteville$61K
- Joseph BeckFayetteville$22K
- Gregory OakhillFayetteville$9K
- Matthew LockwoodFayetteville$8K
- K'anne ArthurFayetteville$8K
- Lynsay BrautnickFayetteville$7K
- Brooke BranderFayetteville$6K
- Mitchell RossFayetteville$3K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.